Actively Recruiting
Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma
Led by City of Hope Medical Center · Updated on 2026-04-22
28
Participants Needed
4
Research Sites
443 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of this study is to determine if giving an experimental drug called venetoclax in combination with lenalidomide and rituximab is safe and effective for treating people with Mantle Cell Lymphoma (MCL).
CONDITIONS
Official Title
Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older
- Diagnosis of mantle cell lymphoma established by tissue examination
- Signs, symptoms, or test results related to mantle cell lymphoma
- Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2
- Enrollment in and willingness to comply with the Revlimid REMS® safety program
- Females of childbearing potential must follow scheduled pregnancy tests
- Men and women of childbearing potential must use effective contraception
- Adequate organ function as determined by study requirements
- Ability to understand and sign informed consent
- Ability to swallow oral capsules or tablets
You will not qualify if you...
- Prior chemotherapy treatment for mantle cell lymphoma
- Pregnant or breastfeeding women
- Peripheral neuropathy of grade 2 or higher
- Known history of central nervous system or leptomeningeal involvement by mantle cell lymphoma
- Significant cardiovascular disease
- Conditions that may impair drug absorption
- Uncontrolled active infection or recent use of intravenous anti-infective treatment within 2 weeks
- History of stroke or brain bleeding within 6 months
- Participation in another clinical trial at the same time
- Use of moderate or strong CYP3A inhibitors or inducers within 1 week prior to treatment
- Psychiatric or social conditions limiting study compliance
- Known HIV positivity
- Active hepatitis B or C infection with detectable viral load
- Prior cancers except certain treated skin or cervical cancers or cancers disease-free for at least 2 years
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 4 locations
1
City of Hope Medical center
Duarte, California, United States, 91010
Actively Recruiting
2
University of Michigan
Ann Arbor, Michigan, United States, 48109
Actively Recruiting
3
The Ohio State University Comprehensive Cancer Center
Columbus, Ohio, United States, 43210
Not Yet Recruiting
4
University of Virginia Cancer Center
Charlottesville, Virginia, United States, 22903
Actively Recruiting
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here